Glen­mark plans to launch an­tivi­ral drug for Covid-19 in next few days

Hindustan Times (Jalandhar) - - HTSPOTLIGH­T - Rhythma Kaul letters@hin­dus­tan­times.com

NEW DELHI : Glen­mark Phar­ma­ceu­ti­cals Lim­ited plans to launch its an­tivi­ral drug Favipi­ravir, which pro­duced im­prove­ment of up to 88% in mild to mod­er­ate coro­n­avirus disease cases dur­ing clin­i­cal tri­als, across In­dia by early next week, the com­pany said on Saturday, mak­ing it the first oral an­tivi­ral avail­able un­der emer­gency use au­tho­ri­sa­tion to treat Covid-19 pa­tients in the coun­try.

The drug, mar­keted un­der the brand name Fab­i­Flu, will be mar­keted in some north In­dian states by Saturday evening. Avail­able in a pack of 34 oral ta­bles of 200mg each for ₹3,500, the cost of the 14-day treat­ment will be around ₹14,000.

The dosage reg­i­men is 3,600 mg on day one, and 1,600 mg from day two on­wards for a max­i­mum 14 days.

Emer­gency use means ev­ery pa­tient must give his or her in­formed con­sent be­fore start­ing treat­ment.

“The com­pany has al­ready started pro­duc­tion of the drug. In some states that are closer to our man­u­fac­tur­ing unit in Baddi (Hi­machal) the drug will be rolled out by this (Saturday) evening, and across In­dia we should be able to sup­ply by early next week,” said Su­jesh Va­sude­van, pres­i­dent, In­dia for­mu­la­tions, Mid­dle East and Africa, at Glen­mark.

Ex­perts in the field find the study re­sults promis­ing.

“The ini­tial data looks promis­ing, and we will get to see how well it works once we start us­ing it,” said a se­nior doc­tor treat­ing Covid-19 pa­tients in a pri­vate hos­pi­tal on con­di­tion of anonymity.

EMER­GENCY USE MEANS EV­ERY PA­TIENT MUST GIVE HIS OR HER IN­FORMED CON­SENT BE­FORE START­ING TREAT­MENT

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.